AFP with a cut-off value of 209 ng/ml showed much lower sensitivities for early and all-stage HCC than GNB4 and Riplet (stage I: 47.82% vs. 78.26%; all stages: 61.64% vs. 86.30%). This evidence concerns the gene GNB4 and hepatocellular carcinoma.